Cantor Fitzgerald Estimates Zura Bio FY2026 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Zura Bio in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will post earnings per share of ($0.63) for the year. The consensus estimate for Zura Bio's current full-year earnings is ($0.65) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02).

Several other research firms have also commented on ZURA. HC Wainwright reissued a "buy" rating on shares of Zura Bio in a report on Thursday, April 3rd. Guggenheim restated a "buy" rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital cut their price objective on Zura Bio from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Wednesday, March 26th. Finally, Oppenheimer lowered their target price on Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a report on Friday, May 9th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $14.33.

Zura Bio Trading Down 3.2%

ZURA traded down $0.04 during mid-day trading on Wednesday, hitting $1.22. 391,454 shares of the stock were exchanged, compared to its average volume of 434,394. Zura Bio has a 1-year low of $0.97 and a 1-year high of $5.07. The firm's fifty day moving average is $1.21 and its two-hundred day moving average is $1.63. The company has a market cap of $83.42 million, a PE ratio of -1.74 and a beta of -0.12.

Hedge Funds Weigh In On Zura Bio

Several large investors have recently added to or reduced their stakes in ZURA. American Century Companies Inc. acquired a new position in Zura Bio during the 4th quarter worth about $27,000. Prudential Financial Inc. bought a new stake in Zura Bio in the 4th quarter valued at $28,000. Two Sigma Advisers LP bought a new position in Zura Bio during the fourth quarter worth about $32,000. ProShare Advisors LLC acquired a new position in shares of Zura Bio during the 4th quarter worth $35,000. Finally, XTX Topco Ltd acquired a new stake in shares of Zura Bio during the fourth quarter valued at about $44,000. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.